ClinicalTrials.gg
Not yet recruitingNCT07135687Updated Nov 19, 2026

Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction

A Phase 4 interventional study of Losartan and Placebo in ACL Injury, ACL Reconstruction and Scar Formation, sponsored by Rush University Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Rush University Medical Center · Phase 4, Interventional, and Other

How we know

Updated Nov 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 176 studies in Anterior Cruciate Ligament Injuries with a site in United States — 44 open to participants now, 62 under way, 3 of them phase 3. Anterior Cruciate Ligament Injuries · United States.

Planned enrollment
19th of 152
144 · median 50
Started
2027
with 1 other
Phase 4
16 of 176
4 open now
Primary completion
2028-10
later than 49 of 61 live
Registered
169th of 176
by date

Among the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, this one is the 19th largest by planned enrollment of the 152 interventional ones that give a count, is one of 2 that started in 2027, is one of 16 in phase 4, reaches primary completion later than 49 of the 61 other live ones, and was the 169th registered.

Anterior Cruciate Ligament Injuries

627 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.

Browse Anterior Cruciate Ligament Injuries studies →

Open to participants now

44 of the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Anterior Cruciate Ligament Injuries studies recruiting now, 27 (22%) set no upper age limit and 92 (75%) stop at 75 or younger; 46 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study to investigate the effect of using losartan (a blood pressure lowering drug with anti-scarring properties) on preventing primary postoperative arthrofibrosis (formation of abnormal scar tissue) in the knees in participants undergoing anterior cruciate ligament (ACL) repair surgery of their knee.

Read the detailed description

Losartan, an angiotensin-II receptor blocker (ARB), approved by the Food and Drug Administration (FDA) for the treatment of hypertension and diabetic nephropathy, has garnered recent interest in the field of orthopedic surgery as an anti-fibrotic (anti-scarring) agent. Losartan's primary mechanism of action as an anti-hypertensive involves acting as a receptor antagonist for angiotensin II, a peptide produced by the liver which causes vasoconstriction, release of anti-diuretic hormone from the pituitary gland, and release of aldosterone from the adrenal glands, among other functions. Losartan secondary function is to act as a TGF-β1 blocker. TGF-β1 has been implicated in pro-fibrotic pathways in multiple organs systems. Losartan, initially as a treatment for hypertension and diabetic nephropathy, was found to have benefits against fibrosis in the renal system. As a result, the use of losartan has gained interest in several other fields in medicine, including plastic surgery for wound healing and keloid prevention, in ophthalmology to prevent corneal scarring, and orthopedic surgery. The potential use of losartan presents an attractive anti-fibrotic prophylaxis candidate against the formation of postoperative arthrofibrosis following ACLR.

03

Conditions studied

  • ACL Injury
  • ACL Reconstruction
  • Scar Formation

Keywords

  • ACL
  • Postoperative Arthrofibrosis
  • Losartan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be undergoing a primary ACLR with or without the following:
  • Chondroplasty
  • Synovectomy
  • Loose body removal
  • Removal of hardware
  • Meniscal surgery (excluding meniscal allograft transplantation/MAT)
  • Lateral extra-articular tenodesis
  • Must have skeletal maturity in the distal femur and proximal tibial physes
  • Must be age 18 years or older at time of enrollment

Exclusion criteria

Exclusion Criteria:

  • \<18 years at time of enrollment
  • No diagnosis of ACL tear
  • ACL repairs
  • Revision ACL reconstructions
  • Open distal femur or proximal tibia physes
  • Major concomitant procedures (such as osteotomy, MAT, or cartilage restoration surgery)
  • History of prior proximal or distal femur fracture (including those receiving nonoperative treatment)
  • History of prior ipsilateral femur or tibia osteomyelitis
  • Medical history
  • History of hypotensive disease, including postural orthostatic hypotension syndrome (POTS), autonomic dysreflexia, or Shy-Drager syndrome (aka multiple system atrophy), baseline hypotension \<90 systolic or \<60 diastolic mmHg.
  • History of significant hepatic disease (liver transplantation, cirrhosis of any cause, or any liver disease with classification B or C) due to hepatic metabolism of ARBs.
  • Chronic kidney disease
  • Rheumatologic disorders on immunologic medications
  • Current medications including diuretics (i.e. furosemide), lithium, and spironolactone
  • Current hypertension with prescription of an ARB or ACE-I
  • Allergy to losartan
  • Current pregnancy or breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Losartan

    The experimental arm (Arm 1) will receive 25mg losartan daily for 3 days followed by 50 mg losartan daily for 25 days.

    Drug: Losartan

  • Placebo comparator
    Placebo

    The placebo arm (Arm 2) will receive a placebo tablet with the same appearance and frequency to that of the losartan group.

    Other: Placebo

Interventions

  • Two types of losartan capsules will be compounded by combining a broken-up 25mg or 50mg losartan tablet and microcrystalline cellulose placebo filler to eliminate rattling of the broken tablet inside of the capsule. The 25mg losartan capsules will be yellow and the 50 mg losartan capsules will be blue.

  • OtherPlacebo

    The placebo capsules will consist of microcrystal cellulose and will come in yellow and blue to appear identical to the losartan capsules.

06

What researchers measure

Primary outcomes

  1. Range of Motion

    Range of motion measured from baseline to 12 months

    Time frame: 12 months

07

Study locations

1 site
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
    • Andrew BI, MD · ContactAndrew.Bi@rushortho.com
    • Jorge Chahla, MD, PhD · ContactJorge.Chahla@rushortho.com
    • Jorge Chahla, MD PhD · Principal investigator
    • Andrew Bi, MD PhD · Principal investigator
    • Adam Yanke, MD, PhD · Sub investigator
    • Brian Cole, MD · Sub investigator
    • Catherine Yuh, MD · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Aug 2027; primary completion for Oct 2028, 14 months later.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Aug 2027, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 22, 2025
StartEst.
Aug 2027was Aug 2026
Primary completionEst.
Oct 2028
CompletionEst.
Dec 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Aug 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Aug 2026→Aug 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07135687
Collaborators
Arthroscopy Association of North America
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Aug 2027 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Jorge Chahla, MD, PhD
Contact
Jorge.chahla@rushortho.com
(312) 432-2452
Andrew Bi, MD
Contact
Andrew.Bi@rushortho.com
Jorge Chahla, MD, PhD
principal investigator · Rush University Medical Center
Andrew Bi, MD
principal investigator · Rush University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion